Alzheimer's disease
Neurology· 3 reviewed drugs· 11352 cited findings behind them
What the regulatory reviews cover
Regulatory review documents in this library for Alzheimer's disease include Kisunla, Leqembi, and Exelon Patch. Kisunla is indicated for adult patients with mild cognitive impairment and mild AD dementia due to Alzheimer’s disease who are apolipoprotein E ε4 (ApoE ε4) non-carriers with confirmed amyloid pathology. For Kisunla, the iADRS slowing (donanemab vs placebo) was 32. Leqembi is indicated for the treatment of Alzheimer’s disease, with treatment initiated in patients with mild cognitive impairment or mild dementia stage of disease. Leqembi demonstrated a change from baseline in brain amyloid plaque (Centiloids) of -73.5.
Exelon Patch is indicated for mild to moderate dementia associated with Parkinson’s disease (PDD). For Exelon Patch, the ADAS-cog mean change from baseline (15 cm patch) was -0.2. It is important to note that different drugs were studied in different trials, and therefore, the figures presented are not head-to-head comparisons.
The drugs — one cited result each
| Kisunla Eli Lilly and Company | iADRS slowing (donanemab vs placebo): 32 Eli Lilly and Company — Kisunla EMA EPAR public assessment r, p.58 |
| Leqembi Eisai Co., Ltd. | Change from baseline in brain amyloid plaque (Centiloids): -73.5 EISAI INC — Leqembi FDA Summary Review (NDA/BLA 761269, 2023, p.22 |
| Exelon Patch Novartis AG | ADAS-cog mean change from baseline (15 cm patch): -0.2 SANDOZ — Exelon FDA Review (NDA/BLA 022083, 2016), p.36 |
Different drugs were studied in different trials — these figures are not head-to-head comparisons.
Explore the full evidence
Every finding behind these drugs — searchable, comparable and answerable in plain language — is in the Neurology research library →
Lists reflect the regulatory review documents in this library, not all therapies that exist. Educational reference only — not medical or investment advice.